StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Friday morning. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald reiterated an overweight rating and set a $2.50 price target on shares of VolitionRx in a report on Thursday, May 16th.

VolitionRx Price Performance

VNRX stock opened at $0.60 on Friday. The firm has a market capitalization of $49.51 million, a P/E ratio of -1.30 and a beta of 1.13. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.38. The company’s 50 day simple moving average is $0.64 and its 200-day simple moving average is $0.78.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.